KS Biomedix Secures European Deal Over TransMID™-R
By Business Review Editor
Pharma Deals Review: Vol 2002 Issue 29 (Table of Contents)
Published: 2 Oct-2002
DOI: 10.3833/pdr.v2002.i29.990 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
KS Biomedix entered into a licensing agreement with Nycomed for its TransMID™-R for the treatment of high grade glioma with a value up to US$60 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS